HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

VS 261

structure given in first source

Also Known As:

4-(tert-butoxycarbonylamino)-3--hydroxy-5-(4-hydroxyphenyl)-2-pentafluorophenyl-2-pentenenitrile; VS-261

Networked: 23 relevant articles (2 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Hydrocarbons: 1713
  - Halogenated Hydrocarbons: 42
    - Fluorinated Hydrocarbons: 4
      - Fluorocarbons: 1209
        VS 261: 23
- Nitriles: 227
  - VS 261: 23

Experts

1.	Aytolign, Habtu Adane: 1 article (02/2022)
2.	Chekole, Animut Tilahun: 1 article (02/2022)
3.	Kassa, Adugna Aregawi: 1 article (02/2022)
4.	Yadeta, Senait Aweke: 1 article (02/2022)
5.	Ashayeri, Kimberly: 1 article (01/2022)
6.	Braly, Brett: 1 article (01/2022)
7.	Buckland, Aaron J: 1 article (01/2022)
8.	Cheng, Ivan: 1 article (01/2022)
9.	Eisen, Leon: 1 article (01/2022)
10.	Fatemi, Parastou: 1 article (01/2022)

Related Diseases

1.	Diarrhea 07/01/2015 - "However, the AUC0-24 and C0 levels of gefitinib in the patients with diarrhea or hepatotoxicity were significantly greater than in those without (diarrhea: AUC0-24, 14,246 vs. 8918 ng · h/mL, P = .006; C0: 421 vs. 261 ng/mL, P = .002; hepatotoxicity: AUC0-24, 12,967 vs. 8473 ng · h/mL, P = .024; C0: 420 vs. 248 ng/mL, P = .002). "
2.	Calcinosis 08/01/1993 - "Co-treatment with VER reduced the severity of microcalcification in CsA groups, particularly N animals, increased CCR on day 14 in the Sl (196 +/- 23 vs 391 +/- 64) and days 21 and 28 in N (141 +/- 14 vs 357 +/- 32 and 152 +/- 28 vs 261 +/- 20) groups, respectively but had no effect on the magnitude of enzymuria, despite significantly increased trough whole blood CsA levels (20-30%) in both Sl and N groups. "
3.	Body Weight (Weight, Body) 01/01/2021 - "Groups 1 and 2 presented lower body weight gains than groups 3 (213.89 ± 13.77 vs 261.63 ± 34.20 grams (g), p = 0.04) and 4 (209.84 ± 27.40 vs 257.57 ± 32.95 g, p = 0.04), respectively. " 12/01/2005 - "Cows housed in the barn lost less body weight and returned to initial body weight sooner and had lower mean concentrations of plasma nonesterified fatty acids (464 vs. 261 mEq/L) than those managed on pasture. " 01/01/2019 - "Two-week hypoxia changed the body weight (- 31% vs. - 27%, respectively, P = NS), blood hemoglobin (+ 25% vs. + 27%, P = NS) and nitrates+nitrites (+ 175% vs. + 261%, P = 0.007), right ventricle fibrosis (+ 814% vs. + 317%, P < 0.0001), right ventricle hypertrophy (+ 84% vs. + 49%, P = 0.007) and systolic pressure (+ 108% vs. + 41%, P = 0.001), pulmonary vessel density (+ 61% vs. + 46%, P = NS), and the frequency of small (< 50 µm wall thickness) vessels (+ 35% vs. + 13%, P = 0.0001). "
4.	Infections 05/15/2011 - "Ad-14 infection was associated with higher admission temperature (38.3°C [interquartile range, (IQR) 37.7, 39.4] vs 37.3°C [IQR (36.7, 38.5)]; P < .01) and lower white blood cell count (8.3 × 1000 cells/μL [IQR, 5.7, 12.4] vs 13 × 1000 cells/μL [IQR, 7.5, 12.9]; P = .01), neutrophil count (6.7 × 1000 cells/μL [IQR, 2.8, 9.7] vs 9.7 × 1000 cells/μL [IQR, 5.6, 12.1]; P = .02), lymphocyte count (0.9 × 1000 cells/μL [IQR, 0.8, 1.1] vs 1.3 × 1000 cells/μL [IQR, 1, 1.9]; P = .001), and platelet count (210 × 1000 cells/μL [IQR, 145, 285] vs 261 × 1000 cells/μL [IQR, 238, 343]; P < .01). " 05/01/1998 - "These infections occurred earlier in the CF lung transplant recipients (median POD 10 vs 261) (p<0.01). "
5.	Fibrosis (Cirrhosis) 01/01/2020 - "Out of 835 CHC patients, overall, genotype 3 had higher LSM (11.3 vs 7.62, p = 0.01), higher aspartate aminotransferase (AST) (88.4 vs 68.6, p = 0.02), and low platelets (228.4 vs 261, p = 0.03) with higher prevalence of cirrhosis (115/415 vs 25/245, p = 0.01) than nongenotype 3. However, decompensation rates were not significantly different between two groups (32/115 vs 7/25, p = 0.98). " 01/01/2019 - "Two-week hypoxia changed the body weight (- 31% vs. - 27%, respectively, P = NS), blood hemoglobin (+ 25% vs. + 27%, P = NS) and nitrates+nitrites (+ 175% vs. + 261%, P = 0.007), right ventricle fibrosis (+ 814% vs. + 317%, P < 0.0001), right ventricle hypertrophy (+ 84% vs. + 49%, P = 0.007) and systolic pressure (+ 108% vs. + 41%, P = 0.001), pulmonary vessel density (+ 61% vs. + 46%, P = NS), and the frequency of small (< 50 µm wall thickness) vessels (+ 35% vs. + 13%, P = 0.0001). "

Related Drugs and Biologics

1.	Gefitinib (Iressa)
2.	Hemoglobins (Hemoglobin)
3.	Nonesterified Fatty Acids (NEFA)
4.	Cholesterol
5.	Aspartate Aminotransferases (Aspartate Transaminase)
6.	Analgesics (Analgesic Drugs)

Related Therapies and Procedures

1.	Operative Time
2.	Cardiopulmonary Resuscitation (CPR)
3.	Therapeutics
4.	Length of Stay